MedTrace Logo

Adapting and Pilot Testing a Loneliness Intervention for Cancer Survivors

NCT07418437 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2026-03-13

No results posted yet for this study

Summary

Loneliness, which is the perceived lack of social support and connection, has increased substantially in the past decade and is adversely affecting the health and wellbeing of cancer survivors. The study seeks to test an intervention that builds on the principles of social prescribing, and targets loneliness to determine if it improves overall wellness and quality of life among cancer survivors.

Conditions

  • Cancer Survivorship
  • Loneliness

Interventions

BEHAVIORAL

Social Prescribing Group

Those in the Social Navigation intervention group will meet with the facilitator through a virtual visit (HIPAA-compliant videoconferencing or phone call based on patient preference) over the course of 9 weeks. Each virtual visit will last approximately 60 minutes. During the group intake visit, the facilitator will guide participants to complete an inventory of the participant's existing social network, former social network, and interests. Using this, in the second visit, the facilitator will work with the participants one-on-one to develop an action plan to promote, establish or re-establish social connections. The action plan will be referenced and refined throughout the course of the following 7 weeks. They will suggest specific social activities and connect patients to resources such as, community-based organizations or local social groups matched to individual participant interest to assist with social connection.

BEHAVIORAL

Usual Care

Those randomized to the Usual Care group will receive usual care from their primary care clinician. At the conclusion of the study (after the final outcomes are collected), they will be offered a list of possible community-based organizations for social connection.

Sponsors & Collaborators

Principal Investigators

  • Sebastian Tong, MD, MPH · University of Washington

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-09
Primary Completion
2026-09-30
Completion
2026-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07418437 on ClinicalTrials.gov